Metagenomics

Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Retrieved on: 
금요일, 11월 17, 2023
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Karyotype, Chromosome, Plant, Acute myeloid leukemia, Collection, Risk, CMA, Cytogenetics, Phase Genomics, Animal, Genomics, Metagenomics, Booth, Genome, Risk assessment, Cancer, AML, Antibiotics, Medical imaging

The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).

Key Points: 
  • The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).
  • Phase Genomics addresses these legacy challenges with the combination of its OncoTerra technology and Element’s AVITI system for next-generation sequencing, providing a high-resolution alternative for comprehensive, streamlined risk stratification in the research setting.
  • The next-generation cytogenomics all-in-one approach is primed to replace fragmented legacy tests with a single, rapid assay,” said Ivan Liachko, founder and CEO of Phase Genomics.
  • Discover more about next-generation cytogenomics powered by proximity ligation technology in four presentations at AMP23 , or connect with the Phase Genomics team at Booth 810.

Global Metagenomics Sequencing Research Report 2023:Government Funding Accelerates Innovations - Forecasts to 2028

Retrieved on: 
목요일, 11월 9, 2023
Metagenomics, Water, Infection, Health, Pesticide, Reagent, Conditional sentence, Environmental health, Skin, Diabetes, Carbon, Atmosphere, Fungus, Research, Virus, Enzyme, Fertilisation, Software, Application, Growth, Immune system, DSM-IV codes, Plant, Farmer, Soil, Competition, Ecology, Environmental monitoring, Public, Natural Resources, Traction, Cancer, Climate change, Investment, Agriculture, Inflammatory bowel disease, Built environment, Pharmaceutical industry, Medical imaging, Fine chemical

The growth of the Global Metagenomics Sequencing Market has been significantly propelled by the continual advancements in sequencing technologies.

Key Points: 
  • The growth of the Global Metagenomics Sequencing Market has been significantly propelled by the continual advancements in sequencing technologies.
  • Notably, next-generation sequencing and single-molecule sequencing technologies have ushered in a transformative era by substantially augmenting the throughput, precision, and expediency of metagenomics sequencing.
  • Moreover, the advent of portable sequencing technologies has expanded the horizons of metagenomics sequencing by enabling on-site sequencing in field settings.
  • Further, expected to drive the growth of the Global Metagenomics Sequencing Market as farmers, researchers, and agribusinesses adopt metagenomics sequencing to optimize crop production and improve sustainability.

Phase Genomics Named Metagenomics Innovation Of The Year for 2023 by BioTech Breakthrough Awards for “Transformative Innovations Advancing the Frontiers of Global Public Health”

Retrieved on: 
수요일, 11월 8, 2023
Software, Research, Pharmaceutical, Technology, Infectious Diseases, Agritech, Genetics, Artificial Intelligence, Health Technology, Science, Biotechnology, Health, Other Science, Metagenomics, Genomics, Behavior, NIAID, Environmental health, News, Doctor of Philosophy, Virus, Nature, AMR, Biology, Education for librarianship, Bacteria, Phase Genomics, Bill & Melinda Gates Foundation, Agriculture, Pharmaceutical industry, Fine chemical, Vaccine

Phase Genomics, Inc. , a global provider of industry-leading genomic solutions, has been awarded the “Metagenomics Innovation Of The Year” distinction for 2023 in the third annual BioTech Breakthrough Awards program.

Key Points: 
  • Phase Genomics, Inc. , a global provider of industry-leading genomic solutions, has been awarded the “Metagenomics Innovation Of The Year” distinction for 2023 in the third annual BioTech Breakthrough Awards program.
  • “The rapid, scalable, resource-efficient metagenomics solution from Phase Genomics unlocks immense improvements across the fields of global, public and environmental health.
  • We’re thrilled to recognize them with the ‘Metagenomics Innovation of the Year’ award,” said Bryan Vaughn, managing director of BioTech Breakthrough.
  • “It is an honor to be recognized as leaders at the forefront of metagenomics innovation by BioTech Breakthrough.

Global Metagenomics Sequencing Market Trends, Opportunities, Competition and Forecasts, 2018-2022 & 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
수요일, 11월 8, 2023
Pharmaceutical, Science, Health, Other Science, Metagenomics, Water, Infection, Pesticide, Reagent, Conditional sentence, Environmental health, Skin, Diabetes, Carbon, Atmosphere, Fungus, Research, Virus, Enzyme, Fertilisation, Application, Software, Growth, Immune system, DSM-IV codes, Plant, Farmer, Soil, Competition, Ecology, Environmental monitoring, Public, Natural Resources, Traction, Cancer, Climate change, Investment, Agriculture, Inflammatory bowel disease, Built environment, Pharmaceutical industry, Medical imaging, Fine chemical

Personalized medicine is a key driver for the growth of the Global Metagenomics Sequencing Market.

Key Points: 
  • Personalized medicine is a key driver for the growth of the Global Metagenomics Sequencing Market.
  • The growth of the Global Metagenomics Sequencing Market has been significantly propelled by the continual advancements in sequencing technologies.
  • Notably, next-generation sequencing and single-molecule sequencing technologies have ushered in a transformative era by substantially augmenting the throughput, precision, and expediency of metagenomics sequencing.
  • Further, expected to drive the growth of the Global Metagenomics Sequencing Market as farmers, researchers, and agribusinesses adopt metagenomics sequencing to optimize crop production and improve sustainability.

Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

Retrieved on: 
월요일, 11월 6, 2023
Metagenomics, MD, Doctor of Philosophy, Research, Protein, Epigenomics, Genomics, NGS, Gene, Proteomics, HT, Marketing

The addition of Olink Explore HT significantly increases Novogene AMEA's capabilities and quality of multi-omics research services offerings.

Key Points: 
  • The addition of Olink Explore HT significantly increases Novogene AMEA's capabilities and quality of multi-omics research services offerings.
  • Olink Explore HT represents the state of the art in next generation proteomics, allowing scientists to accurately measure over 5,400 proteins using only 2µl of sample.
  • “The addition of the Olink Explore platform to the Novogene portfolio marks our commitment to delivering the latest multi-omics solutions to the scientific community in Asia Pacific, Middle East and Africa region.
  • Now, with Olink Explore HT, Novogene AMEA will begin offering high-throughput proteomics with industry-leading specificity, helping their customers unravel the intricate connections between genes, proteins, and diseases.

Novogene AMEA adopts Olink® Explore HT platform

Retrieved on: 
월요일, 11월 6, 2023
Metagenomics, MD, Kingdom of Poland, Doctor of Philosophy, Research, Protein, Epigenomics, Genomics, Workflow, Proteomics, HT, Marketing, Fine chemical

SINGAPORE, Nov. 6, 2023 /PRNewswire/ -- Novogene Asia Pacific Middle East and Africa (AMEA), a leading provider of genomic services and solutions is pleased to announce the adoption of the Olink® Explore HT platform.

Key Points: 
  • SINGAPORE, Nov. 6, 2023 /PRNewswire/ -- Novogene Asia Pacific Middle East and Africa (AMEA), a leading provider of genomic services and solutions is pleased to announce the adoption of the Olink® Explore HT platform.
  • The addition of Olink Explore HT enhances Novogene AMEA's capabilities and quality of multi-omics research services, providing customers with advanced next-generation proteomics technology to support their ground-breaking research.
  • "The addition of the Olink Explore platform to the Novogene portfolio marks our commitment to delivering the latest multi-omics solutions to the scientific community in Asia Pacific, Middle East and Africa region.
  • "We are immensely pleased to see Olink Explore HT being utilised by Novogene, a leading multiomic service provider, to provide their customers with innovative research services.

Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer

Retrieved on: 
화요일, 10월 10, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Science, Oncology, Diagnosis, Memorial Sloan Kettering Cancer Center, University of Pittsburgh Medical Center, Immunodeficiency, Fred Hutchinson Cancer Research Center, Death, Plasma, DNA, The Study, Risk, National Cancer Institute, Weill Cornell Medicine, University, Loris Karius, MD Anderson Cancer Center, University of Colorado Denver, Principal, University of California, Detection, City, University of Colorado, Bone marrow, Publication, Infection, Bronchoscopy, Duke University Health System, Metagenomics, Patient, Vaccine, Pharmaceutical industry, Pneumonia

“Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.

Key Points: 
  • “Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.
  • Identifying the specific cause of pneumonia in patients with blood cancers who are often severely immunocompromised is difficult and critically important to successful treatment.
  • “This well-designed clinical trial conducted at leading academic centers shows that the Karius Test is highly valuable in immunocompromised patients with suspected infection,” said Dr. Ned Sharpless, former Director, National Cancer Institute, and newest Karius board member.
  • “These patients have much to gain through an improved etiologic diagnosis, and the better and more directed treatment of these infections that make this possible,” said Brad Perkins, Chief Medical Officer at Karius.

Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

Retrieved on: 
수요일, 9월 27, 2023
Professional Services, Oncology, Start-Up, Consumer, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Baby, Maternity, Women, Biotechnology, Health, Pregnancy, Female, STI, Infection, Trichomoniasis, Gonorrhea, Discovery, Woman, Infertility, Prescription, Biomarker, Fungus, IRB, Data, Patient, Stanford University Medical Center, Preterm birth, Oncology nursing, Fertility, Chlamydia, Growth, Metagenomics, Bacteria, Research, Recurrence, System, PCR, Birth control, Nursing, Virtue

Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.

Key Points: 
  • Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.
  • Research has also uncovered groundbreaking links between the vaginal microbiome and infertility, STIs, preterm birth, gynecologic cancers, and more.
  • The Evvy Vaginal Health Test leverages mNGS to screen for all bacteria and fungi that have been isolated from the vaginal and urinary tract in a single swab.
  • They launched an integrative, personalized, AI-powered vaginal healthcare platform, and ran an IRB-approved study clinically validating that the platform improves the vaginal microbiome.

Element Biosciences Announces Over 100 Commercial Orders of its AVITI System and Surpasses Q2 Sales Goals

Retrieved on: 
수요일, 9월 6, 2023
Metagenomics, University, EMBL, DNA sequencing, NGS, Research, Genome, Tavarua, Doctor of Philosophy, BioRxiv, Government, Creativity, Whole genome sequencing, Chemistry, Laboratory, FACMG, European, Element, RNA-Seq, Entrepreneurship, Massachusetts Institute of Technology, Health, SVP, European Molecular Biology Laboratory, Video game, Fine chemical, Antibiotics, Q2

/PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced it has exceeded 100 orders of the AVITI System. With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks. The company has seen triple digit quarter-on-quarter growth since launch, and in Q2 reached an estimated 15 percent of the total sales of mid-throughput sequencing instruments, just one year after its first commercial shipments. Element has also signed distribution agreements with 11 distributors across the globe.

Key Points: 
  • With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks.
  • "Today's milestone validates the market demand for truly differentiated solutions that help customers achieve more with sequencing, regardless of scale.
  • "As a data-driven company, we are committed to setting ambitious goals and consistently delivering data and outcomes that surpass expectations.
  • Over 40 percent of sales were multi-unit orders and Element also welcomed repeat customers adding capacity to their existing fleet of AVITI instruments.

Delve Bio Appoints Jim Stuart as Chief Commercial Officer

Retrieved on: 
월요일, 8월 28, 2023
Science, Other Science, Research, General Health, Health, Infectious Diseases, Genetics, Clinical Trials, Quest Diagnostics, University, Bio, Genomics, University of California, San Francisco, Infection, Jim Stuart, Personalized medicine, Genentech, Fungus, Cerebrospinal fluid, Dicarboxylic acid, Parasitism, Metagenomics, Delve, Bacteria, Anne, Encephalitis, Virus, Meningitis, Management, Pharmaceutical industry

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

Key Points: 
  • Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.
  • “We’re delighted to welcome Jim to our growing team,” said Brad Murray, co-founder and CEO of Delve Bio.
  • “His track record of driving commercial success in molecular diagnostics gives us full confidence in his ability to increase physician and patient access to our mNGS test.”
    Mr. Stuart joins Delve from Invitae, where he held positions of increasing responsibility, starting as the first employee on the commercial team and culminating as senior vice president, commercial.
  • Delve Bio emerged from stealth with $35 million in Series A financing in June.